Tekla Life Sciences Investors Announces Results of Annual Shareholders Meeting

BOSTON, MA, June 15, 2017 – The Board of Trustees of Tekla Life Sciences Investors (HQL), is pleased to announce the results from the Fund’s annual shareholder meeting held today.

Shareholders re-elected Oleg Pohotsky and William Reardon as Trustees of Tekla Life Sciences Investors.

The shareholders also ratified the selection of Deloitte & Touche LLP as the Independent Registered Public Accountants of the Fund for its fiscal year ending September 30, 2017.

In addition, the shareholders rejected a shareholder proposal to reorganize the Board of Trustees into one class with each Trustee subject to election each year.

Tekla Life Sciences Investors (NYSE: HQL) is a closed-end fund that invests in companies in the life sciences and other healthcare industry.

Tekla Capital Management LLC is a Boston, MA based healthcare-focused investment manager with approximately $3.1 billion of assets under management as of March 31, 2017. Tekla also serves as investment adviser to three other closed-end funds: Tekla Healthcare Investors (NYSE: HQH), Tekla Healthcare Opportunities Fund (NYSE: THQ) and Tekla World Healthcare Fund (NYSE: THW).  Information regarding the Fund and Tekla Capital Management LLC can be found at www.teklacap.com.

Destra Capital Investments is the Fund’s marketing and investor support services agent. Please contact Destra Capital Investments at (877)855-3434 if you have any questions.